Latest Headlines

Latest Headlines

Shire's Gaucher drug beats Cerezyme in bone study

The company announced trial results showing its Gaucher disease drug Vpriv improved bone density in patients' spines, but Sanofi's Cerezyme didn't.

Protalix scores $25M milestone from Pfizer

Pfizer followed GlaxoSmithKline and other pharma companies that journeyed into the rare disease arena, paying $60 million upfront to partner with Protalix and agreeing to pay out up to $55 million in milestones.

Pfizer aims at Genzyme with Gaucher drug approval

In announcing the FDA approval of its new Gaucher disease treatment Elelyso, Pfizer put Genzyme firmly in its sights.

FDA OK for Gaucher drug opens new market for Pfizer, Protalix

After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).